Kallyope Inc., a NYC-based biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, raised $112m in Series C financing.
Backers included existing investors The Column Group, Lux Capital, Polaris Partners, Euclidean Capital, Two Sigma Ventures, Illumina Ventures, Alexandria Venture Investments, and Bill Gates and new investors Casdin Capital, Greenspring Associates, and two unnamed leading institutional investors.
The company intends to use the funds to advance its portfolio of programs and its first clinical trials.
Led by CEO Nancy Thornberry, Kallyope is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company’s cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to new therapeutics. The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D.
Headquartered at the Alexandria Center® for Life Science in New York City, Kallyope also announced its lead program targeting satiety circuits for weight loss, with clinical testing expected to begin later this year. A second program targeting gut barrier function with potential relevance for inflammatory bowel disease (IBD) and several other diseases is anticipated to enter the clinic soon after. In addition, the company continues to advance a broad portfolio of programs for gastrointestinal, CNS, and inflammatory disorders.